MedTrace Logo

Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia

NCT05728944 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 229

Last updated 2026-02-25

Study results available
· View outcomes & findings →

Summary

Phase 3 Efficacy Study to evaluate the Safety and Efficacy of LNZ100 \& LNZ101 for the Treatment of Presbyopia

Conditions

  • Presbyopia
  • Near Vision
  • Refractive Error
  • Eye Diseases

Interventions

DRUG

Aceclidine+Brimonidine combination ophthalmic solution

Aceclidine + Brimonidine combination ophthalmic solution

DRUG

Aceclidine ophthalmic solution

Aceclidine ophthalmic solution

DRUG

Vehicle

Proprietary vehicle ophthalmic solution

Sponsors & Collaborators

  • LENZ Therapeutics, Inc

    lead OTHER

Principal Investigators

  • Kris Gambelin, BS · LENZ Therapeutics, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-06
Primary Completion
2023-12-14
Completion
2024-01-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05728944 on ClinicalTrials.gov